Autopsy report · NCT01930175
Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris
Cause of deathFunding or business
“The study recruitment was terminated in Dec-2015 for strategic reasons related to the development of the compound.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 5 years 9 months before it stopped.
- 13 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Pemphigus Vulgaris
- Interventions
- VAY736; Placebo
- Participants
- 13
- Sites
- 5
- Countries
- Austria, Bulgaria, Taiwan, United States
Trials that died the same way
- Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
“The study was terminated due to recruitment challenges” - Early Versus Late Amniotomy Following EAB Cervical Ripening
“Study was terminated due to difficulties in recruitment” - A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
“Study terminated as part of strategic considerations” - Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery
“The study was terminated due to a considerably lower recruitment rate than anticipated” - Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks
“Study terminated due to inadequate recruitment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.